Evidence map›Paper›PMID 40603002›Full record

ArticleACS nano2025

Self-Assembly of Accumulated Sphingolipids into Cytotoxic Fibrils in Globoid Cell Leukodystrophy and Their Inhibition by Small Molecules In Vitro.

Sourav Kumar, Evelina Nikelshparg, Jana Pilátová, Ashim Paul, Vijay Kumar, Gil Koren, Roy Beck, Henrik H Jensen, Daniel Segal

Erratum issuedAbstract read
In one paragraph

Article in ACS nano, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

9 authors.

Sourav KumarShmunis School of Biomedicine and Cancer Research, George Wise Faculty of Life Sciences, Tel Aviv University, Tel Aviv 6997801, Israel.ORCID 0000-0002-2518-3742
Evelina NikelshpargDepartment of Life Sciences, Ben-Gurion University of the Negev, Beer Sheva 8855630, Israel.
Jana PilátováShmunis School of Biomedicine and Cancer Research, George Wise Faculty of Life Sciences, Tel Aviv University, Tel Aviv 6997801, Israel.
Ashim PaulStructural Biology & Bioinformatics Division, Indian Institute of Chemical Biology, Raja S. C. Mullick Road, Jadavpur, Kolkata 700032, India.ORCID 0000-0003-2182-8248
Vijay KumarShmunis School of Biomedicine and Cancer Research, George Wise Faculty of Life Sciences, Tel Aviv University, Tel Aviv 6997801, Israel.ORCID 0000-0002-3980-1345
Gil KorenThe Raymond & Beverly Sackler School of Physics and Astronomy, The Center for Nanoscience and Nanotechnology, and The Center for Physics and Chemistry of Living Systems, Tel Aviv University, Tel Aviv 6997801, Israel.
Roy BeckThe Raymond & Beverly Sackler School of Physics and Astronomy, The Center for Nanoscience and Nanotechnology, and The Center for Physics and Chemistry of Living Systems, Tel Aviv University, Tel Aviv 6997801, Israel.ORCID 0000-0003-3121-4530
Henrik H JensenDepartment of Chemistry, Aarhus University, Aarhus C 8000, Denmark.ORCID 0000-0003-2738-4502
Daniel SegalShmunis School of Biomedicine and Cancer Research, George Wise Faculty of Life Sciences, Tel Aviv University, Tel Aviv 6997801, Israel.ORCID 0000-0002-6777-505X

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Globoid cell leukodystrophy (GLD) is a rare hereditary inborn error of metabolism due to recessive mutations that cause loss of function of the enzyme galactosylceramidase (GALC). This results in the accumulation of the sphingolipids galactosylceramide (GalCer) and galactosylsphingosine (GalSph) in the lysosomes of neuronal cells. The accumulated GalCer and GalSph in cerebral macrophages of GLD patients are neurotoxic to oligodendrocytes and Schwann cells, leading to demyelination in the nervous system. The disease typically presents with infantile onset in the first six months of life and death by age 2. Here, we identified a supramolecular structure of GalCer and GalSph that may contribute to GLD pathology. Using biophysical assays commonly used for studying proteinaceous amyloids, e.g., amyloid-specific dyes, microscopical imaging, and a series of analytical methods (FTIR, PXRD, and SAXS), we demonstrate that both GalCer and GalSph can self-assemble in vitro into highly organized fibrils reminiscent of fibrils of amyloidogenic proteins. These fibrils exhibit significant cytotoxicity to both neuronal and oligodendroglial cells. Using an inhibitor of the GALC enzyme in cell culture to mimic the GLD pathophysiology, we could detect the accumulation of these fibrils in cells. We also observed that small molecules, which are bona fide inhibitors of proteinaceous amyloids, effectively mitigated the formation of the GalCer and GalSph fibrillar structures in vitro. Finally, the small molecule ameliorated the cytotoxic effects of the sphingolipid fibrils in SH-SY5Y cells, suggesting a potential avenue for therapeutic intervention in GLD orphan disease.

Indexed as

AmyloidGalactosylceramidesLeukodystrophy, Globoid CellPsychosineSmall Molecule LibrariesSphingolipidsAnimalsGalactosylceramidaseHumansAmyloidGalactosylceramidaseGalactosylceramidesPsychosineSmall Molecule LibrariesSphingolipidsapoptosisgalactosylceramidegalactosylsphingosinegloboid cell leukodystrophyself-assemblysmall molecule inhibitorssphingolipids

Identifiers

PMID40603002
PMCPMC12269364

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.